In Silico fragment-based drug design using a PASS approach

References

• Gorse , AD . 2006 . Diversity in medicinal chemistry space . Curr. Top. Med. Chem. , 6 : 3 – 18 .
   PubMed Web of Science ®Google Scholar
• Fischer , M and Hubbard , RE . 2009 . Fragment-based ligand discovery . Mol. Int. , 9 : 23 – 30 .
   Google Scholar
• Overington , JP , Al-Lazikani , B and Hopkins , AL . 2006 . How many drug targets are there? . Nat. Rev. Drug Discov. , 5 : 993 – 996 .
   PubMed Web of Science ®Google Scholar
• Wanga , Y , Lub , H , Zhua , Q , Jiangb , S and Liaoc , Y . 2001 . Structure-based design . synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41, Bioorg. Med. Chem. Lett. , 20 : 189 – 193 .
   Google Scholar
• Barreiro , G , Kim , JT , Guimarães , CRW , Bailey , CM , Domaoal , RA , Wang , L , Anderson , KS and Jorgensen , WL . 2007 . From docking false-positive to active anti-HIV agent . J. Med. Chem. , 50 : 5324 – 5329 .
   PubMed Web of Science ®Google Scholar
• Kandil , S , Biondaro , S , Vlachakis , D , Cummins , A-C , Coluccia , A , Berry , C , Leyssen , P , Neyts , J and Brancale , A . 2009 . Discovery of a novel HCV helicase inhibitor by a de novo drug design approach . Bioorg. Med. Chem. Lett. , 19 : 2935 – 2937 .
   PubMed Web of Science ®Google Scholar
• Cumming , JN , Le , TX , Babu , S , Carroll , C , Chen , X , Favreau , L , Gaspari , P , Guo , T , Hobbs , DW , Huang , Y , Iserloh , U , Kennedy , ME , Kuvelkar , R , Li , G , Lowrie , J , McHugh , NA , Ozgur , L , Pan , J , Parker , EM , Saionz , K , Stamford , AW , Strickland , C , Tadesse , D , Voigt , J , Wang , L , Wu , Y , Zhang , L and Zhang , Q . 2008 . Rational design of novel . potent piperazinone and imidazolidinone BACE1 inhibitors, Bioorg. Med. Chem. Lett. , 18 : 3236 – 3241 .
   PubMed Web of Science ®Google Scholar
• Ji , H , Stanton , BZ , Igarashi , J , Li , H , Martásek , P , Roman , LJ , Poulos , TL and Silverman , RB . 2008 . Minimal pharmacophoric elements and fragment hopping . an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors, J. Am. Chem. Soc. , 130 : 3900 – 3914 .
   Google Scholar
• Novoseletsky , VN , Pyrkov , TV and Efremov , RG . 2010 . Analysis of hydrophobic interactions of antagonists with the beta2-adrenergic receptor . SAR QSAR Environ. Res. , 21 : 37 – 55 .
   PubMed Web of Science ®Google Scholar
• Cao , Y , Jiang , T and Girke , T . 2008 . A maximum common substructure-based algorithm for searching and predicting drug-like compounds . Bioinformatics. , 24 : 366 – 374 .
   Web of Science ®Google Scholar
• Masciocchi , J , Frau , G , Fanton , M , Sturlese , M , Floris , M , Pireddu , L , Palla , P , Cedrati , F , Rodriguez-Tome , P and Moro , S . 2009 . MMsINC: A large-scale chemoinformatics database . Nucleic Acids Res. , 37 : 284 – 290 .
   PubMed Web of Science ®Google Scholar
• Du , QS , Huang , RB , Wei , YT , Pang , ZW , Du , LQ and Chou , KC . 2009 . Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design . J. Comput. Chem. , 30 : 295 – 304 .
   PubMed Web of Science ®Google Scholar
• B.M Spowage, C.L Bruce, and J.D Hirst, Interpretable correlation descriptors for quantitative structure-activity relationships, J. Cheminf. 1:22 (2009). Available at http://www.jcheminf.com/content/pdf/1758-2946-1-22.pdf
   Google Scholar
• Myint , KZ , Ma , C , Wang , L and Xie , X-Q . 2011 . Fragment-similarity-based QSAR (FS-QSAR) algorithm for ligand biological activity predictions . SAR QSAR Environ. Res. , 22 : 385 – 410 .
   PubMed Web of Science ®Google Scholar
• D.A. Filimonov and V.V. Poroikov, Probabilistic approach in activity prediction, in Chemoinformatics Approaches to Virtual Screening, A. Varnek and A. Tropsha, eds., RSC Publishing, Cambridge (UK), 2008, pp. 182–216
   Google Scholar
• Devillers , J , Dore , JC , Guyot , M , Poroikov , V , Gloriozova , T , Lagunin , A and Filimonov , D . 2007 . Prediction of biological activity profiles of cyanobacterial secondary metabolites . SAR QSAR Environ. Res. , 18 : 629 – 643 .
   PubMed Web of Science ®Google Scholar
• Geronikaki , A , Druzhilovsky , D , Zakharov , A and Poroikov , VV . 2008 . Computer-aided predictions for medicinal chemistry via Internet . SAR QSAR Environ. Res. , 19 : 27 – 38 .
   PubMed Web of Science ®Google Scholar
• Filz , O , Lagunin , A , Filimonov , D and Poroikov , VV . 2008 . Computer-aided prediction of QT-prolongation . SAR QSAR Environ. Res. , 19 : 81 – 90 .
   PubMed Web of Science ®Google Scholar
• Poroikov , VV , Filimonov , DA , Borodina , Yu.V. , Lagunin , AA and Kos , A . 2000 . Robustness of biological activity spectra predicting by computer program PASS for noncongeneric sets of chemical compounds . J. Chem. Inf. Comput. Sci. , 40 : 1349 – 1355 .
   PubMedGoogle Scholar
• Boda , K , Seidel , T and Gasteiger , J . 2007 . Structure and reaction based evaluation of synthetic accessibility . J. Comput. Aided Mol. Des. , 21 : 311 – 325 .
   PubMed Web of Science ®Google Scholar
• Lewell , XQ , Judd , DB , Watson , SP and Hann , MM . 1998 . RECAP–retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry . J. Chem. Inf. Comput. Sci. , 38 : 511 – 522 .
   PubMedGoogle Scholar
• Douguet , D , Munier-Lehmann , H , Labesse , G and Pochet , S . 2005 . LEA3D: A computer-aided ligand design for structure-based drug design . J. Med. Chem. , 48 : 2457 – 2468 .
   PubMed Web of Science ®Google Scholar
• Nicolaou , CA , Apostolakis , J and Pattichis , CS . 2009 . De novo drug design using multiobjective evolutionary graphs . J. Chem. Inf. Model. , 49 : 295 – 307 .
   PubMed Web of Science ®Google Scholar
• A.S. Tarendash, Let's Review Chemistry, the Physical Setting, 4-th ed., Barron's Educational Series, New York, 2006
   Google Scholar
• H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N.Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242. Available at http:/rcsb.org/pdb/home/home.do
   Google Scholar
• Golovin , A , Dimitropoulos , D , Oldfield , T , Rachedi , A and Henrick , K . 2005 . MSDsite: A database search and retrieval system for the analysis and viewing of bound ligands and active sites . PROTEINS: Struct. Funct. Bioinf. , 58 : 190 – 199 .
   PubMed Web of Science ®Google Scholar
• A. Golovin and K. Henrick, MSDMotif: Exploring protein sites and motifs, BMC Bioinf. 9 (2008), pp. 312-323. Available at http://ebi.ac.uk/pdbe-site/pdbemotif/
   Google Scholar
• Lindauer , K , Bendic , C and Suhnel , J . 1996 . HBExplore – a new tool for identifying hydrogen bonding patterns in biological molecules . Comput. Appl. Biosci. , 12 : 281 – 289 .
   PubMedGoogle Scholar
• Pedretti , A , Villa , L and Vistoli , G . 2003 . Atom-type description language: A universal language to recognize atom types implemented in the Vega program . Theor. Chem. Acc. 2003 , 109 : 229 – 232 .
   Web of Science ®Google Scholar
• C. Spatz, Basic Statistics: Tales of Distributions (7 th ed.), Wadsworth Publishing, Belmont, 2001
   Google Scholar
• Stubbs , MT , Huber , R and Max-Planek , WB . 1995 . Crystal structures of factor Xa specific inhibitors in complex with trypsin: Structural grounds for inhibition of factor Xa and selectivity against thrombin . FEBS Lett. , 375 : 103 – 107 .
   PubMed Web of Science ®Google Scholar
• Bauer , KA . 2003 . New pentasaccharides for prophylaxis of deep vein thrombosis, pharmacology . Chest. Pharmacol. Chem. , 124 : 364S – 370S .
   Google Scholar
• Sánchez-del-Campo , IL , Sáez-Ayala , M , Chazarra , S , Cabezas-Herrera , J and Rodríguez-López , JN . 2009 . Binding of natural and synthetic polyphenols to human dihydrofolate reductase . J. Mol. Sci. , 10 : 5398 – 5410 .
   Web of Science ®Google Scholar
• C. Avendano and J. Carlos Menendez, Medicinal Chemistry of Anticancer Drugs, Elsevier, Amsterdam, 2008
   Google Scholar
• McCormack , JJ . 1981 . Dihydrofolate reductase inhibitors as potential drugs . Med. Res. Rev. , 1 : 303 – 331 .
   PubMed Web of Science ®Google Scholar
• Cody , V , Galitsky , N , Luft , JR , Pangborn , W , Gangjee , A , Devraj , R , Queener , SF and Blakley , RL . 1997 . Comparison of ternary complexes of pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate . Acta Crystallogr. D. Biol. Crystallogr. , 53 : 638 – 64 .
   PubMed Web of Science ®Google Scholar
• Battershell , C , Malhotra , D and Hopfinger , AJ . 1981 . Inhibition of dihydrofolate reductase: Structure-activity correlations of quinazolines based upon molecular shape analysis . J. Med. Chem. , 24 : 812 – 818 .
   PubMed Web of Science ®Google Scholar
• Popova , VM , Chana , DCM , Fillinghama , YA , Yeea , WA , Wrightb , DL and Andersonb , AC . 2006 . Analysis of complexes of inhibitors with Cryptosporidium hominis DHFR leads to a new trimethoprim derivatives . Bioorg. Med. Chem. Lett. , 16 : 4366 – 4370 .
   PubMed Web of Science ®Google Scholar
• Cody , V and Pace , J . 2011 . Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5000-(x-carboxyalkoxy)benzyl]-pyrido[2,3-d] pyrimidine derivatives . Acta Cryst. , 67 : 1 – 7 D .
   Web of Science ®Google Scholar
• Dev , IK , Yates , BB , Leong , J and Dallas , WS . 1988 . Functional role of cysteine-146 in Escherichia coli thymidylate synthase . Proc. Nadl. Acad. Sci. , 85, : 1472 – 1476 .
   PubMed Web of Science ®Google Scholar
• Stout , TJ and Stroud , RM . 1996 . The complex of the anti-cancer therapeutic . BW1843U89, with thymidylate synthase at 2.0 A resolution: Implications for a new mode of inhibition, Struct. , 4 : 67 – 77 .
   Google Scholar
• Rutenber , EE and Stroud , RM . 1996 . Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: Assessing specificity and affinity . Struct. , 4 : 1317 – 1324 .
   Web of Science ®Google Scholar
• M.E.M Noble and J.A. Endicott, Pharmacology & Therapeutics Volume 82, Issues 2-3, May-June 1999, Pages 269-278 Chemical Inhibitors of Cyclin-Dependent Kinases: Insights into Design from X-Ray Crystallographic Studies
   Google Scholar
• Pratt , DJ , Bentley , J , Jewsbury , Ph. , Boyle , FT , Endicott , JA and Noble , MEM . 2006 . Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity . J. Med. Chem. , 49 : 5470 – 5477 .
   PubMed Web of Science ®Google Scholar
• Hoessel , R , Leclerc , S , Endicott , JA , Nobel , MEM , Lawrie , A , Tunnah , P , Leost , M , Damiens , E , Marie , D , Marko , D , Niederberger , E , Tang , W , Eisenbrand , G and Meijer , L . 1999 . Indirubin . the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases, Nat. Cell Bio. , 1 : 60 – 67 .
   Google Scholar
• Yu , L and Dennis , EA . 1991 . Critical role of a hydrogen bond in the interaction of phospholipase A2 with transition-state and substrate analogues . Proc. Natl. Acad. Sci. , 88 : 9325 – 9329 .
   PubMed Web of Science ®Google Scholar
• Féthière , J , Tsuda , Y , Coulombe , R , Konishi , Y and Cygler , M . 1996 . Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin . Protein Sci. , 5 : 1174 – 1183 .
   PubMed Web of Science ®Google Scholar
• Mlinsek , G , Oblak , M , Hodoscek , M and Solmajer , T . 2007 . Thrombin inhibitors with novel P1 binding pocket functionality: Free energy of binding analysis . J. Mol. Model. , 13 : 247 – 254 .
   PubMed Web of Science ®Google Scholar
• Ripka , WC . 1997 . New thrombin inhibitors in cardiovascular disease . Curr. Opin. Chem. Biol. , 1 : 242 – 253 .
   PubMed Web of Science ®Google Scholar
• Bourne , Y , Taylor , P , Radi , Z and Marchot , P . 2003 . Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site . The EMBO J. , 22 : 1 – 12 .
   PubMed Web of Science ®Google Scholar
• Ibrahim , F , Guillaume , YC , Thomassin , M and André , C . 2009 . Magnesium effect on the acetylcholinesterase inhibition mechanism: A molecular chromatographic approach . Talanta , 79 : 804 – 809 .
   PubMed Web of Science ®Google Scholar
• Georgieva , DN , Rypniewski , W , Gabdoulkhakov , A , Genov , N and Betzela , C . 2004 . Asp49 phospholipase A2–elaidoylamide complex: A new mode of inhibition . Biochem. Biophys. Res. Commun. , 319 : 1314 – 1321 .
   PubMed Web of Science ®Google Scholar